Mikael Dolsten - 18 Jun 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director
Issuer ticker: RCKT
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 19:59:59 UTC
Prior SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Mikael Dolsten

Key filing fact

Mikael Dolsten filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 06 Jul 2026.

Key facts

This page summarizes Mikael Dolsten's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 19:59.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001437590 Primary reporting owner

Dolsten Mikael

Relationship: Director
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Mikael Dolsten
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value
Shares: +22,862
Change %: +52%
Price: $0.000000^*
Shares after: 67,082
Date: 18 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +64,860
Change %
Price: $0.000000^*
Shares after: 64,860
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,860
Exercise price: $3.35
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.

Footnote F2

This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.